Dr. Agarwal's Health Care Limited

Valuation elevated at PE 108.22 against ROE of 6.84%—verify whether this pricing reflects justified growth expectations or is speculative

Subsidiary-dependent earnings: standalone net profit of ₹16.67 Cr in Jun 2026 represents only 30% of consolidated net profit, creating concentration risk

Standalone operating margin volatility: OPM ranged from 22.29% (Sep 2025) to 27.75% (Jun 2026)—verify the drivers and persistence of recent margin levels

Public shareholding of just 1.98% with 57.96% FII concentration—verify liquidity and index composition stability

Consolidated revenue grew 23% from ₹499 Cr (Sep 2025) to ₹614 Cr (Jun 2026)—verify if this reflects organic growth or acquisition contributions

Standalone revenue also grew 24% over three quarters (₹309 Cr to ₹382 Cr)—verify whether driven by bed utilization gains or pricing increases

Consolidated OPM at 27–28% provides headroom for net margin improvement if SG&A or financing costs decline—verify cost structure trends

D/E ratio of 0.08 provides substantial debt capacity for acquisition-led consolidation in the hospital sector—verify capital allocation strategy